The Patent Finder

Hutchmed Limited

9 patents currently held · Updated Nov 19, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Previously recorded as Hutchison Medipharma Limited (to 2022)

3
Ending by 2030
May 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jun 30, 2027
    The maintenance fee for Crystalline Forms of 6-((6,7-Dimethoxyquinazolin-4-yl)oxy)-N,2-Dimethylbenzofuran-3-Carboxamide (US 10,519,142) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
  • 1 fee due Oct 16, 2027
    The maintenance fee for Crystalline Forms of 6-((6,7-Dimethoxyquinazolin-4-YL)OXY)-N,2-Dimethylbenzofuran-3-Carboxamide (US 11,958,838) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 21, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,829,574Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
In force
 · USPTO record
In forceUSPTO record
US 8,212,033Use of substituted quinazoline compounds in treating angiogenesis-related diseases
In force
 · USPTO record
In forceUSPTO record
US 8,658,658Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
In force
 · USPTO record
In forceUSPTO record
US 10,519,142Crystalline Forms of 6-((6,7-Dimethoxyquinazolin-4-yl)oxy)-N,2-Dimethylbenzofuran-3-Carboxamide
In force
 · High confidence
In forceHigh confidence
US 11,046,674Crystalline Forms of 6-((6,7-Dimethoxyquinazolin-4-YL)OXY)-N,2-Dimethylbenzofuran-3-Carboxamide
In force
 · High confidence
In forceHigh confidence
US 11,958,838Crystalline Forms of 6-((6,7-Dimethoxyquinazolin-4-YL)OXY)-N,2-Dimethylbenzofuran-3-Carboxamide
In force
 · High confidence
In forceHigh confidence
US 12,600,713Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide
In force
 · High confidence
In forceHigh confidence
US 12,030,951ANTI-OX40 Antibody and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 12,715,857Tricyclic Compounds and Uses Thereof
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 9: 1 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited